Fully closed-loop system with insulin lispro plus pramlintide may benefit type 1 diabetes

NEW ORLEANS — Adults with type 1 diabetes had a similar time in range using automated insulin delivery with ultrarapid-acting insulin lispro-aabc and pramlintide compared with insulin lispro-aabc alone, according to a speaker. In findings from a randomized crossover trial presented at the American Diabetes Association Scientific Sessions, use of a fully closed-loop automated insulin delivery